Advanced Filters
noise
Found 65,199 clinical trials
F Francisco Guinot Jimeno, DDS, MsC

Effectiveness of Rotating System and Single File Reciprocating System in Temporal Molars

Is an in vivo study to test the effectiveness of the reciprocating system Reciproc blue and the rotating system VDW.ROTATE in primary molars.

4 - 8 years of age All Phase N/A
A Andreas Schneeweiss, MD

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

In early breast cancer (eBC), pathological complete response (pCR) after neoadjuvant therapy acts as surrogate marker for metastasis and overall survival. Therapy intensification by adding an adjuvant therapy line (post-neoadjuvant treatment) substantially lowers the risk of relapse in high-risk breast cancer patients with residual disease after neoadjuvant treatment (non-pCR). While …

18 years of age All Phase 2
J Jean-Christophe LECLERE, Dr

Boarding Ring Glasses Versus Placebo Glasses or Not Glasses in the Treatment of Vestibular Neuritis

Vestibular neuritis is a brutal and continuous dizzying syndrome of peripheral (vestibular) origin without cochlear or other associated involvement. Specifically, vestibular neuritis is inflammation of the nerve that innervates the vestibular canals (the inner ear). It is characterized by the sudden onset of intense and prolonged vertigo accompanied by postural …

18 years of age All Phase N/A
B Bernhard Grubmüller, MD

Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer

Prostate cancer is the most common non-skin cancer diagnosed among men and the second leading cause of male cancer deaths in the United States. In 2013, it is estimated that 29,270 men have died from prostate cancer. Although radiation and surgery are quite effective for localized disease, there is no …

18 - 75 years of age Male Phase N/A
R Revathy Munuswamy, PhD

The Impact of Diet on the Gut-Microbiota-Brain Axis

This study aims to investigate the effects of an 8-week dietary intervention on cognitive function, stress, and the gut microbiota in healthy adults with low fibre intake.

18 - 50 years of age All Phase N/A
V Victoria Tumanova, PhD

Effects of Emotional Processes on Speech Motor Control in Early Childhood Stuttering.

This study will compare speech variability between preschool-age children who stutter and typically fluent, age-matched peers. Differences in emotional reactivity, regulation and speech motor control have been implicated in stuttering development in children. This study seeks to understand further how these processes interact. Children will repeat a simple phrase after …

3 - 10 years of age All Phase N/A
H Hannah J. Sachs, MPA

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

The aim of this study is to utilize neurophysiologic assessments, behavioral measures and clinical measures to assess how much deficits associated with Fragile X Syndrome from pre-dose to post-dose using pharmacology.

18 - 45 years of age All Phase 2

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in patients with advanced solid tumors. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of SHR-A2102 in phase II study.

18 years of age All Phase 1

Effect of Phaseolus Vulgaris L. Dry Extract on the Modulation of Weight and Metabolic Parameters

Evaluation of the efficacy of Phaseolus vulgaris L. dry extract on weight modulation.

18 - 60 years of age Male Phase N/A
K Kaichao Feng, MD

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

In preclinical study, investigators have demonstrated that the newly developed pan-T booster (harbouring CD40 agonist and one T cell costimulator agonist) co-expressing MSLN CAR T cell possess more powerful antitumor activity than previously reported MSLN-CAR T cells. In this clinical trial, enrolled patients receive an initial dose of pan-T booster …

18 - 75 years of age All Phase 1/2

Simplify language using AI